Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a narrative review synthesizing literature on CVD epidemiology, pathophysiology, and emerging therapies including phytotherapy, without original data or comparative evidence to support specific clinical claims.
A systematic review synthesizing heterogeneous preclinical and clinical evidence with conflicting findings, raising mechanistic questions about PCSK9 in breast cancer rather than answering them definitively.
A narrative review synthesizing mechanistic evidence and existing literature on shared pathways between CAD and malignancy, raising hypotheses about causal mechanisms rather than testing them empirically.
This is a narrative review article that synthesizes existing knowledge about IL-6 in cardiovascular disease and rheumatic conditions, proposing IL-6 as a therapeutic target, but does not report original empirical results or trial outcomes.
Novel reagent validation in porcine cells and PBMCs showing CD69 detection capacity and early activation kinetics, but lacks clinical efficacy data, comparative validation against gold standards, or multi-site reproducibility.
Narrative review synthesizing evidence on Lp(a) pathophysiology and clinical role in coronary and aortic valve disease, with guidance on emerging therapies, but lacking new primary trial data or definitive outcome evidence.
This is an editorial overview and state-of-the-art review summarizing current understanding of residual lipid risk, therapeutic advances, and clinical management recommendations rather than reporting original research findings.